Biogen Inc. (BIIB)
140.88
-0.50 (-0.35%)
At close: Mar 21, 2025, 3:59 PM
140.90
0.01%
After-hours: Mar 21, 2025, 04:56 PM EDT
-0.35% (1D)
| Bid | 140.75 |
| Market Cap | 20.62B |
| Revenue (ttm) | 9.52B |
| Net Income (ttm) | 1.64B |
| EPS (ttm) | 11.18 |
| PE Ratio (ttm) | 12.6 |
| Forward PE | 8.84 |
| Analyst | Hold |
| Ask | 141.8 |
| Volume | 1,126,508 |
| Avg. Volume (20D) | 1,524,800.2 |
| Open | 141.24 |
| Previous Close | 141.38 |
| Day's Range | 139.87 - 142.08 |
| 52-Week Range | 128.51 - 238.00 |
| Beta | 0.01 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an ad...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Sep 17, 1991
Employees 7,605
Stock Exchange NASDAQ
Ticker Symbol BIIB
Website https://www.biogen.com
Analyst Forecast
According to 26 analyst ratings, the average rating for BIIB stock is "Hold." The 12-month stock price forecast is $210, which is an increase of 49.06% from the latest price.
Stock ForecastsNext Earnings Release
Biogen Inc. is scheduled to release its earnings on Apr 23, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-4.28%
Biogen shares are trading lower after the company ...
Unlock content with
Pro Subscription
4 months ago
-1.28%
Biogen shares are trading lower after Needham downgraded the stock from Buy to Hold.
